secwatch.observer — SEC 8-K summary
======================================

Issuer:     NEUROCRINE BIOSCIENCES INC (NBIX)
CIK:        0000914475
Form:       8-K
Filed at:   2022-05-04T23:59:59+00:00
Accession:  0000914475-22-000021
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Neurocrine Q1: INGREZZA sales $303M (+32% YoY), GAAP EPS $0.14, reaffirms FY guidance
--------------------------------------------------------------------------------

- Net product sales $303M (+32% YoY); total revenue $310.6M incl $5.6M collaboration revenue.
- GAAP net income $13.9M ($0.14 diluted EPS) vs $32.1M ($0.33) in Q1 2021.
- Non-GAAP net income $29.7M ($0.30 diluted EPS) vs $48.8M ($0.50) prior year.
- Cash and marketable securities $1.2B; reiterates 2022 INGREZZA sales guidance $1.25-$1.35B.
- Positive Phase 3 valbenazine data in Huntington chorea; sNDA filing expected H2 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/914475/000091447522000021/0000914475-22-000021-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/914475/000091447522000021/nbix-20220504.htm
  HTML page:      https://secwatch.observer/filing/0000914475-22-000021

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer